Corcept Therapeutics $CORT
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS6
PHASE 3 / 2-31
RECRUITING3
READOUTS ≤12 MONTHS2
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Relacorilant 150 mg NCT05257408 |
P3 | Active, not recruiting | Ovarian Neoplasm; Fallopian Tube Neoplasms | 381 | 2025-03-31 (+10 mo) |
| Nenocorilant 200 mg NCT07276373 |
P1/2 | Recruiting | Neoplasms | 50 | 2026-09 |
| DAZALS NCT05407324 |
P2 | Active, not recruiting | Amyotrophic Lateral Sclerosis | 279 | 2026-10 (+29 mo) |
| relacorilant NCT03604198 |
P2 | Active, not recruiting | Cushing Syndrome | 125 | 2026-12 (+65 mo) |
| Relacorilant NCT07259317 |
P2 | Recruiting | Adenocarcinoma; Carcinoma, Pancreatic Ductal | 80 | 2027-09 |
| Relacorilant 150 mg once daily (QD) NCT06906341 |
P2 | Recruiting | Ovarian Cancer; Fallopian Tube Cancer | 270 | 2027-12 (+16 mo) |